Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease
2016
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI